Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Aerie

Tariff Pressures Loom Over American Eagle's Outlook Despite Recent Gains

Retailers are navigating a complex landscape marked by shifting consumer preferences and economic uncertainties, prompting them to adapt strategies for sustained growth. Amid these challenges, American Eagle Outfitters, Inc. (NYSE:AEO) has shown resilience by outperforming financial expectations, even as broader market trends pose ongoing hurdles.

Benzinga

Sydney Sweeney Couldn’t Save American Eagle Stock. Here’s Why Analysts Think You Should Ditch AEO Here.

American Eagle is a beaten-down stock that trades over 60% below its all-time high in August 2025. Can AEO stock recover over the next 12 months?

Barchart

Is The Sydney Sweeney Boost Already Fading For American Eagle Stock?

American Eagle Outfitters Inc. (NYSE:AEO) shares slipped Monday after fresh concerns emerged over slowing sales momentum, tariff headwinds, and limited earnings visibility, raising doubts about the retailer’s ability to sustain its recent buzz from celebrity-driven marketing and denim demand.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Hanesbrands vs. American Eagle Outfitters: Which Apparel Retail Stock Should You Consider?

The apparel retail industry is thriving due to the growing consumer demand for premium products. Amid this, let’s compare apparel stocks Hanesbrands (HBI) and American Eagle Outfitters (AEO) to analyze which apparel retail stocks should one consider. Read on to find out….

StockNews.com

3 Apparel Brands Gaining Popularity Among Millennials

The apparel industry is thriving, fueled by millennial-driven trends like sustainability, digital-first shopping habits, and increasing discretionary spending. Against this dynamic backdrop, fundamentally robust stocks like Abercrombie & Fitch (ANF), American Eagle Outfitters (AEO), and Revolve Group (RVLV) are not only resonating with this influential demographic but also emerging as…

StockNews.com

American Eagle Sues Amazon Over Alleged Sale Of Aerie 'Knock-offs'

American Eagle has filed a suit against Amazon after allegedly selling knock-offs of its Aerie products.

International Business Times

I Spent 24 Hours With The Industry's Top Leaders—Here's How It Went

Inspired to a new level.

Marie Claire

Read news from The Economist, FT, and more,
with one subscription

Gen-Z implores millennials to ditch leggings for flared yoga pants

‘The flared legging versus yoga pants debate has officially commenced,’ writer says

The Independent UK

Gen-Z implores millennials to ditch leggings for flared yoga pants

‘The flared legging versus yoga pants debate has officially commenced,’ writer says

The Independent UK

14 best black swimsuits that are utterly timeless and exude 'Quiet Luxury'

A summer essential, these are the best black swimsuits to shop right now

Woman & Home

15 best one-piece swimsuits that’ll make you want to book a vacation

The best one-piece swimsuits deliver on design, fabric and fit for a failsafe pool-side look

Woman & Home

The 28 most famous plus size models in the world - and how to follow them

These are 28 of the most famous plus size models in the world from Ashley Graham to Tess Holliday

Woman & Home

Aerie links with disability-focused Liberare for sexy, accessible intimates

Its partnership with intimates label Liberare focuses on accessibility first.

Input

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application to evaluate Tegoprubart for the prevention of organ rejection in patients receiving a kidney transplant. Eledon shares traded in a range of $2.89 to $3.16 on a day volume of 31.27 thousand…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Aerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease Study

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has dosed the first patient in the Phase 3 COMET-2 study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

US Food and Drug Administration

59 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.